Kapoor Sorabh, Jain Gaurav, Sewkani Ajit, Sharma Sandesh, Patel Kailash, Varshney Subodh
Department of Surgical Gastroenterology, Bhopal Memorial Hospital and Research Centre, Bhopal, India.
J Surg Res. 2006 Apr;131(2):256-60. doi: 10.1016/j.jss.2005.12.008. Epub 2006 Feb 2.
Orally administered gastrografin has been used for early resolution of postoperative small bowel obstruction (POSBO) and to reduce the need for surgery in various studies. However the studies have reported conflicting results as patients with complete obstruction and equivocal diagnosis of bowel strangulation were also included.
We carried out a prospective study to evaluate the efficacy of gastrografin in patients with partial adhesive small bowel obstruction. Patients with suspected strangulation, complete obstruction, obstructed hernia, bowel malignancy, and radiation enteritis were excluded. Sixty-two patients with partial adhesive small bowel obstruction were given an initial trial of conservative management of 48 h. Thirty-eight patients improved within 48 h and the other 24 were given 100 ml of undiluted gastrografin through the nasogastric tube. In 22 patients the contrast reached the colon within 24 h. In the remaining two patients the contrast failed to reach the colon and these underwent surgery.
The use of gastrografin avoided surgical intervention in 91.3% (22 of 24) patients who failed conservative management of POSBO. Gastrografin also decreased the overall requirement for surgical management of POSBO from the reported rate of 25 to 30% to 3.2% (2 of 62).
Use of gastrografin in patients with partial POSBO helps in resolution of symptoms and avoids the need for surgical management in the majority of patients.
在各项研究中,口服泛影葡胺已被用于早期解决术后小肠梗阻(POSBO)并减少手术需求。然而,这些研究报告的结果相互矛盾,因为其中还纳入了完全性梗阻和肠绞窄诊断不明确的患者。
我们进行了一项前瞻性研究,以评估泛影葡胺对部分粘连性小肠梗阻患者的疗效。排除疑似绞窄、完全性梗阻、梗阻性疝、肠道恶性肿瘤和放射性肠炎的患者。62例部分粘连性小肠梗阻患者首先接受了48小时的保守治疗试验。38例患者在48小时内病情改善,另外24例通过鼻胃管给予100毫升未稀释的泛影葡胺。22例患者的造影剂在24小时内到达结肠。其余2例患者造影剂未能到达结肠,这2例患者接受了手术。
对于POSBO保守治疗失败的患者,使用泛影葡胺避免了91.3%(24例中的22例)的手术干预。泛影葡胺还将POSBO手术治疗的总体需求率从报告的25%至30%降至3.2%(62例中的2例)。
对部分POSBO患者使用泛影葡胺有助于缓解症状,并避免大多数患者进行手术治疗。